Minato-ku, Japan
Minato-ku, Japan

Time filter

Source Type

Patent
University of Occupational, Environmental Health Japan and Sbi Pharmaceuticals Co. | Date: 2015-02-19

[Problem to be Solved] It is an object of the present invention to provide a composition, which induces immunity to tumor cells and is also able to induce inhibition of tumor growth. [Solution] Provided is a composition for inducing tumor immunity, comprising ALAs.


Patent
SBI Pharmaceuticals Co. and National Center For Child Health And Development | Date: 2017-04-05

Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.


Patent
SBI Pharmaceuticals Co. and Tokushima University | Date: 2015-05-27

Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.


Patent
Tokyo University of Agriculture and SBI Pharmaceuticals Co. | Date: 2016-09-07

The object of the present invention to provide an agent effective for treating and preventing e.g. a disease caused by reduction in frataxin production. The present invention provides a frataxin enhancer comprising 5-aminolevulinic acid (ALA) or a derivative thereof or salts thereof, as well as a therapeutic and/or prophylactic agent for a disease caused by reduction in frataxin production.


Patent
Kumamoto University, University of Occupational, Environmental Health Japan and SBI Pharmaceuticals Co. | Date: 2015-10-21

[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.


A pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease; and a method for preventing/treating an adult disease by using the same. A composition for preventing/ameliorating an adult disease such as metabolic syndrome, diabetes, hyperlipidemia, hypertension, impaired liver function, renal failure, adiposity, erectile dysfunction, menopausal disorder, shoulder discomfort, and low back pain, comprising 5-aminolevulinic acid (ALA), its derivative, or salt thereof, preferably comprising ALA, its derivative, or salt thereof, and an iron compound such as sodium ferrous citrate, iron sodium citrate and iron ammonium citrate; a food or food material for preventing/ameliorating an adult disease comprising the composition; and a method for using the composition for preparing an agent for preventing/ameliorating an adult disease.


Patent
SBI Pharmaceuticals Co. and National Center For Child Health And Development | Date: 2016-03-09

The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.


Patent
SBI Pharmaceuticals Co. and National Center For Child Health And Development | Date: 2016-03-09

The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.


Patent
SBI Pharmaceuticals Co. and National Center For Child Health And Development | Date: 2015-05-20

An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.


Patent
SBI Pharmaceuticals Co. and Osaka City University | Date: 2016-04-27

The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Loading SBI Pharmaceuticals Co. collaborators
Loading SBI Pharmaceuticals Co. collaborators